The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Open-label add-on treatment trial of minocycline in fragile X syndrome.
Open accessAbstract
BACKGROUND: Fragile X syndrome (FXS) is a disorder characterized by a variety of disabilities, including cognitive deficits, attention-deficit/hyperactivity disorder, autism, and other socio-emotional problems. It is hypothesized that the absence of the fragile X mental retardation protein (FMRP) leads to higher levels of matrix metallo-proteinase-9 activity (MMP-9) in the brain. Minocycline inhibits MMP-9 activity, and alleviates behavioural and synapse abnormalities in fmr1 knockout mice, an established model for FXS. This open-label add-on pilot trial was conducted to evaluate safety and efficacy of minocycline in treating behavioural abnormalities that occur in humans with FXS. METHODS: Twenty individuals with FXS, ages 13-32, were randomly assigned to receive 100 mg or 200 mg of minocycline daily. Behavioural evaluations were made prior to treatment (baseline) and again 8 weeks after daily minocycline treatment. The primary outcome measure was the Aberrant Behaviour Checklist-Community Edition (ABC-C) Irritability Subscale, and the secondary outcome measures were the other ABC-C subscales, clinical global improvement scale (CGI), and the visual analog scale for behaviour (VAS). Side effects were assessed using an adverse events checklist, a complete blood count (CBC), hepatic and renal function tests, and antinuclear antibody screen (ANA), done at baseline and at 8 weeks. RESULTS: The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001). The only significant treatment-related side effects were minor diarrhea (n = 3) and seroconversion to a positive ANA (n = 2). CONCLUSIONS: Results from this study demonstrate that minocycline provides significant functional benefits to FXS patients and that it is well-tolerated. These findings are consistent with the fmr1 knockout mouse model results, suggesting that minocycline modifies underlying neural defects that account for behavioural abnormalities. A placebo-controlled trial of minocycline in FXS is warranted. TRIAL REGISTRATION: ClinicalTrials.gov Open-Label Trial NCT00858689.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Reduction of MMP-9 levels with minocycline in humans with FXS (Dziembowska et al., 2013) contributes to reversal of several FXS phenotypes, including behavioral deficits and enhanced auditory electrocortical activity in adults and/or adolescents with FXS (Paribello et al., 2010; Leigh et al., 2013; Schneider et al., 2013).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Paribello et al., 2010
In the citing paper
“an open trial in adolescent and adult males with FXS demonstrated efficacy in all of the outcome measures (127).”
From Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics (2012) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Encyclopedia of Measurement and Statistics
Salkind, N. J. (2007) · Sage eBooks · doi:10.4135/9781412952644 · Cited by 1,594
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
(1985) · PubMed · Cited by 1,427
Encyclopedia of measurement and statistics
(2007) · Choice Reviews Online · doi:10.5860/choice.44-4214 · Cited by 1,389
Dendritic Anomalies in Disorders Associated with Mental Retardation
Kaufmann, W. E. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.10.981 · Cited by 746
Weiler, I. J., Irwin, S. A., Klintsova, A. Y., Spencer, C. M., Brazelton, A. D., Miyashiro, K., Comery, T. A., Patel, B., Eberwine, J., & Greenough, W. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5395 · Cited by 644 · cited 1×
“associates with actively translating ribosomes in dendrites [6,7].”
BackgroundDendritic Spine Structural Anomalies in Fragile-X Mental Retardation Syndrome
Irwin, S. A. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.10.1038 · Cited by 626
Cited by
Sorted by citations
Items 201–224 of 224
Fragile X Syndrome: Steps towards Therapy
Pop, A. (2013) · RePub (Erasmus University Rotterdam)
Social dysfunction and mental retardation
Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.010
Microglial Abnormalities in the Pathophysiology of
Monji, S., Mizoguchi, Y., & Kato, T. A. (2014)
Reber, M. E. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511978616.006
What Mechanisms Induce Methylation of FMR1 Gene Full Mutation? A Still Unanswered Question
Tabolacci, E., & Neri, G. (2016) · Epigenetics and human health · doi:10.1007/978-3-319-27186-6_8
FMRP and the Pathophysiology of Fragile X Syndrome
Barnes, S. A., Thomson, S. R., Kind, P. C., & Osterweil, E. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800109-7.00008-x
de Diego‐Otero, Y., Pérez-Costillas, L., Medina, R. C., Quintero-Navarro, C., Benítez, I. D. P., Casado, Y., & Cobas, C. N. (2017) · Revista Española de Discapacidad · doi:10.5569/2340-5104.05.01.12
Developing a Deeper Understandingof Autism: Connecting Knowledge through Literature Mining
Macedoni-Luk, M., Petri, I., Cestnik, B., & Urban, T. (2011)
Mielke, B. (2014) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4833
Fragile X clinical features and neurobiology
Leigh, M. J., & Hagerman, R. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00022-2
Bacino, C. A., & Lee, B. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00076-2
Steenbergen, A. V., Minhas, A., Lin, T. R., Kaur, M., & Bolduc, F. V. (2023) · Research Square · doi:10.21203/rs.3.rs-3439158/v1
Oligodendroglia and myelin pathology in fragile X syndrome
Hourani, S., & Pouladi, M. A. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16144 · Cited by 1
Novel Drug Targets in Neuro-immune Disorders
Gorain, B., Karmakar, V., Pandey, M., Pooja, P., Sahoo, B. M., Senapati, D., & Bhattamisra, S. K. (2024) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-97-5508-0_9
Protic, D. D., Stojković, M., & Budimirovic, D. B. (2025) · Medicinska istrazivanja · doi:10.5937/medi0-60213 · Cited by 1
Involvement of mGluR5/Homer crosstalk disruption in the pathophysiology of Fragile X Syndrome
Aloisi, E. (2015) · theses.fr (ABES) · doi:10.70675/e628d840zb6adz4e63z9d1fz71559b23fe24
Dissecting the role of calcium signaling in Fragile X syndrome
Castagnola, S. (2019) · theses.fr (ABES) · doi:10.70675/3d35096bz79d0z46edz8a70zb783a8f60257
Felgerolle, C. (2019) · theses.fr (ABES) · doi:10.70675/fbd5cf69zed5az4a57zbfdez48e26a937a72
Pathophysiological consequences of a Fragile X missense mutation
Garcia, M. P. (2020) · theses.fr (ABES) · doi:10.70675/b8e86263z5926z4a83zbaf6z0f61bf2d15f9
Herzog, H. M., Fang, C., Lam, L., Jin, K., Zamarioli, A., Dinh, E., Gupta, C. L., Sharma, A., Moody, T. A., Pierce, J. L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.05.716562
Tetracycline antibiotics: Emerging roles in neuropsychiatric disorders
Acar, A. Ş., Saday, Ö., & Erbaş, O. (2024) · Demiroglu Science University Florence Nightingale Journal of Medicine · doi:10.5606/fng.btd.2024.149
Metadata
- Authors
- Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W.
- Affiliations
- Surrey Place Centre (CA)
- Fraxa Research Foundation (US)
- University of California, Riverside (US)
- Corresponding author
- Paribello, Carlo
- Venue
- BMC Neurology
- Published
- 2010-10-11
- Volume
- 10
- Issue
- 1
- Pages
- 91-91
- ISSN
- 1471-2377 (ISSN-L)
- PMC
- PMC2958860
- OpenAlex
- W2153053291
- Cited by
- 223
- References
- 45
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 9 · 2021: 4 · 2020: 15 · 2019: 10 · 2018: 12 · 2017: 20 · 2016: 12 · 2015: 17 · 2014: 26 · 2013: 30 · 2012: 23
- FWCI
- 14.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Neurology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- FRAXA Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Keywords
- fragile X syndrome, minocycline, MMP-9, FMRP, behavioural abnormalities, irritability, adjunctive therapy, drug safety, adverse events, antinuclear antibodies, Fmr1 knockout mice
- MeSH terms
- Adolescent, Adult, Enzyme Inhibitors, Female, Fragile X Syndrome, Humans, Male, Minocycline, Pilot Projects, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
